Artikel
CXCR7 mediates angiogenesis in human glioma
Suche in Medline nach
Autoren
-
Marin Guentchev
- Klinik für Neurochirurgie, Klinikum Idar-Oberstein, Idar-Oberstein, Germany
-
Andrey Tchorbanov
- Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria
-
Peter Birner
- Klinisches Institut für Pathologie, Medizinische Universität Wien, Vienna, Austria
-
Jochen Tuettenberg
- Klinik für Neurochirurgie, Klinikum Idar-Oberstein, Idar-Oberstein, Germany
| Veröffentlicht: | 21. Mai 2013 |
|---|
Gliederung
Text
Objective: The chemokine receptor CXCR7 and its ligand SDF-1a are expressed on both glioma cells and tumor-associated vessels. Both molecules have been linked to cancer angiogenesis and tumor cell migration where CXCR7 is expressed on the migrating cells and SDF-1a acts as a chemoattractant. Currently there are no functional data on the involvement of CXCR7 and SDF-1a in glioma angiogenesis.
Method: Using immunohistochemical methods, we investigated the influence of CXCR7 and SDF-1a expression on survival in 354 grade II, III and IV human gliomas. In addition we tested the effect of CXCR7 inhibition in a subcutaneous glioma mouse model using the glioma cell line U87MG in 20 mice.
Results: Tumor cell expression of SDF-1a was predictive for poor outcome in low-grade glioma (p=0.001, log rank test), but not in high-grade glioma. Furthermore, selective in vivo inhibition of CXCR7 signaling led to a significant decrease of mean vascular density, in comparison to the control group.
Conclusions: Our results show that angiogenesis in human glioma seems to be at least in part mediated by CXCR7/SDF1a signaling and that vascular penetration into these tumors is likely to be the rate-limiting event in low-grade tumors. Therefore inhibition of CXCR7/SDF1a signaling might be a successful strategy for blocking angiogenesis in human glioma.
